On June 2, 2026, Charlottesville, Virginia-based Contraline announced it had closed a $92.5 million Series B financing — one of the largest rounds ever raised for a male contraceptive — to carry its non-hormonal, reversible products into late-stage clinical development. The round was co-led by BVF Partners and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and existing backers.

Why It Matters

Male contraception is the perennial "coming soon" of reproductive health, and most candidates die in the lab for lack of funding. A $92.5M round co-led by deep-pocketed life-science investors, with GV at the table, is the strongest financial vote of confidence the category has seen — and it arrives as post-Dobbs pressure pushes contraceptive responsibility toward shared models. If either ADAM or NES/T reaches market, it would be the first genuinely new male contraceptive in over a century.

The headline proceeds will fund development of NES/T, an investigational hormonal reversible male contraceptive, with the company targeting a Phase III trial in 2027. Contraline is best known for ADAM, a hydrogel-based implant placed in the vas deferens during a minimally invasive outpatient procedure. ADAM is designed to block sperm for up to two years and then dissolve, restoring fertility without surgery — a fundamentally different proposition from the permanence of a vasectomy.

The raise lands in what investors are calling the "massive white space" of men's reproductive health: despite decades of talk, the contraceptive market still offers men just two real options, condoms and vasectomy, both essentially unchanged for generations. A nine-figure round signals that institutional capital now sees a credible path to a third.

Contraline's progress has been incremental but real — the company has already implanted ADAM in human trial participants and secured clearance to run an early-feasibility study in Australia. The fresh capital is meant to close the gap between promising early data and the large, expensive trials regulators require before approval.

Sources

Update — 2026-06-08

{Initial entry — story first created.}